Angiotensin converting enzyme inhibitor but not calcium blocker down-regulates gene expression of vascular natriuretic peptide receptor in hypertensive rats

Biochem Biophys Res Commun. 1994 Dec 30;205(3):1595-600. doi: 10.1006/bbrc.1994.2849.

Abstract

We have recently found that vascular natriuretic peptide (NP)-A receptor mRNA is upregulated in genetically hypertensive (SHR-SP/Izm) and deoxycorticosterone acetate (DOCA)-salt hypertensive rats. In the present study, we examined the effects of antihypertensive treatments on aortic NP-A receptor mRNA expression in these hypertensive rats using ribonuclease protection assay. Oral administration of an angiotensin converting enzyme inhibitor, derapril, but not a calcium channel blocker, manidipine, produced a significant decrease of the NP-A receptor mRNA level after 4 weeks, while both antihypertensive agents showed similar hypotensive effects. Plasma renin was high in SHR-SP/Izm and low in DOCA-salt rats. These results suggest that the vascular renin-angiotensin system rather than the blood pressure has an important role in the regulation of the vascular NP-A receptor.

MeSH terms

  • Animals
  • Aorta / metabolism
  • Blood Pressure / drug effects
  • Dihydropyridines / pharmacology*
  • Down-Regulation / drug effects
  • Hypertension / drug therapy*
  • Hypertension / genetics
  • Hypertension / physiopathology
  • Indans / pharmacology*
  • Male
  • Nitrobenzenes
  • Piperazines
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Inbred SHR
  • Rats, Wistar
  • Receptors, Atrial Natriuretic Factor / genetics*
  • Renin-Angiotensin System / drug effects
  • Renin-Angiotensin System / physiology

Substances

  • Dihydropyridines
  • Indans
  • Nitrobenzenes
  • Piperazines
  • RNA, Messenger
  • manidipine
  • Receptors, Atrial Natriuretic Factor
  • delapril